Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death

Reuters

Mar 02

Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death

Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020800PRIMZONEFULLFEED9663862) on March 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616327663"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616327663\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616327663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616327663","market":"nz","top_or_hot":-1,"title":"Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020800PRIMZONEFULLFEED9663862) on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020800PRIMZONEFULLFEED9663862) on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL2PYqkS:1","article_id":"2616327663","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616327663","pubTimestamp":1772456581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death. Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","AMRN":"阿玛琳","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Amarin事后REDUCE-IT分析将二十碳五烯酸乙酯与更少的住院以及更少的住院和死亡天数联系起来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"AMRN":0.9},"content_text":"Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death\n    \n\n        Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020800PRIMZONEFULLFEED9663862) on March 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}